Bright Minds Biosciences (DRUG) said Monday it is collaborating with Firefly Neuroscience (AIFF) to provide an analysis of the electroencephalogram data in its phase 2 trial assessing the safety, tolerability and efficacy of BMB-101 to treat absence epilepsy and developmental epileptic encephalopathy.
The trial is expected to enroll 20 adults from 18 to 65 years old, Bright Minds said.
Bright Minds and Firefly have previously collaborated to analyze data from the phase 1 trial of BMB-101 using Firefly's BNA technology platform, the company said.
"This compound is not only poised to make a significant impact in both the [developmental epileptic encephalopathy] and absence epilepsy communities, but also has broad applicability across the 30% of all epilepsy patients who experience drug resistance," said Ian McDonald, Bright Minds chief executive .
Bright Minds shares rose 24% in early trading, while Firefly was up 17%.
Price: 58.74, Change: +11.53, Percent Change: +24.42
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。